GUEST COLUMNISTS

• Last-Mile Lessons For Depot-To-Site Delivery

  Depot-to-site delivery is more than a courier handoff. See how reconciliation gaps, temperature risks, and mismatched SLAs can turn last-mile issues into trial delays.

• Turn AI Visibility Into Action: Build Explanation Layers For Different Stakeholders

  AI visibility isn’t just about being found. Ross Jackson coaches sponsors on how to influence AI to provide clear stakeholder pathways for clinical trial involvement.

• 5 Ways To Enrich The Clinical Trial Ecosystem

  Sponsors must treat sites, PIs, and patients as connected parts of a living clinical trial ecosystem. Here are five ways to help make that happen.

• The Promise Of MRD-Guided CAR-T Treatment

  Minimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.

• Your Trial Shows Up In AI. Now What?

  AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.

• Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials

  Aprea’s Gene Kennedy explains how smart dose escalation, next-gen sequencing, and combination planning are helping the company advance its oncology trial for multiple solid tumor types.

• How A $96M Gift Is Transforming Pediatric Brain Cancer Clinical Trial Infrastructure

  By pairing donor priorities with research needs at Children's National, Milken Institute SPARC is turning philanthropy into faster trials, stronger infrastructure, and long-term care goals.

• Lessons In Forecasting Discipline From A $40B Supply Chain

  Forecasting errors rarely start with the algorithm. They start when protocol changes, enrollment and site data reach the supply plan too late to prevent waste and disruption.